14,397 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,397 shares of the biotechnology company's stock, valued at approximately $479,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Principal Securities Inc. grew its position in shares of Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after buying an additional 373 shares during the last quarter. USA Financial Formulas bought a new stake in Exelixis in the fourth quarter valued at approximately $32,000. Kestra Investment Management LLC bought a new stake in Exelixis in the fourth quarter valued at approximately $39,000. UMB Bank n.a. increased its position in Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 553 shares during the period. Finally, Crowley Wealth Management Inc. bought a new position in Exelixis during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Buying and Selling at Exelixis

In related news, Director Bob Oliver sold 18,647 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the sale, the director now directly owns 33,514 shares in the company, valued at approximately $1,248,396.50. This represents a 35.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares of the company's stock, valued at approximately $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock worth $5,177,234 over the last ninety days. 2.85% of the stock is currently owned by company insiders.

Exelixis Price Performance

Shares of Exelixis stock traded up $0.49 during trading hours on Thursday, hitting $37.27. 649,108 shares of the company's stock traded hands, compared to its average volume of 2,172,191. The company has a fifty day simple moving average of $36.57 and a 200-day simple moving average of $34.45. The stock has a market capitalization of $10.43 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on EXEL shares. Oppenheimer cut shares of Exelixis from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $41.00 to $33.00 in a research report on Friday, January 24th. Truist Financial increased their price target on Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a report on Monday, January 27th. Stifel Nicolaus boosted their price objective on Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a research note on Wednesday, February 12th. Stephens restated an "equal weight" rating and set a $29.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $41.00 target price on shares of Exelixis in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.